Edgewise Therapeutics logo

Edgewise TherapeuticsNASDAQ: EWTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 March 2021

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.95 B
-14%vs. 3y high
85%vs. sector
-vs. 3y high
-vs. sector
-14%vs. 3y high
85%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 23:19:05 GMT
$31.15-$0.80(-2.50%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

EWTX Latest News

Analyst Think There's Still Time to Get in on Edgewise, Up 332%
marketbeat.com25 September 2024 Sentiment: POSITIVE

Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
marketbeat.com19 September 2024 Sentiment: POSITIVE

Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.

EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
zacks.com19 September 2024 Sentiment: POSITIVE

Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
benzinga.com19 September 2024 Sentiment: POSITIVE

On Thursday, Edgewise Therapeutics Inc. EWTX released announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial for obstructive hypertrophic cardiomyopathy.

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
seekingalpha.com05 August 2024 Sentiment: POSITIVE

Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation.

Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
zacks.com17 July 2024 Sentiment: POSITIVE

Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
Zacks Investment Research26 February 2024 Sentiment: NEUTRAL

The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
Zacks Investment Research09 February 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
Zacks Investment Research24 January 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
Zacks Investment Research22 January 2024 Sentiment: POSITIVE

Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.

What type of business is Edgewise Therapeutics?

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

What sector is Edgewise Therapeutics in?

Edgewise Therapeutics is in the Healthcare sector

What industry is Edgewise Therapeutics in?

Edgewise Therapeutics is in the Biotechnology industry

What country is Edgewise Therapeutics from?

Edgewise Therapeutics is headquartered in United States

When did Edgewise Therapeutics go public?

Edgewise Therapeutics initial public offering (IPO) was on 26 March 2021

What is Edgewise Therapeutics website?

https://www.edgewisetx.com

Is Edgewise Therapeutics in the S&P 500?

No, Edgewise Therapeutics is not included in the S&P 500 index

Is Edgewise Therapeutics in the NASDAQ 100?

No, Edgewise Therapeutics is not included in the NASDAQ 100 index

Is Edgewise Therapeutics in the Dow Jones?

No, Edgewise Therapeutics is not included in the Dow Jones index

When was Edgewise Therapeutics the previous earnings report?

No data

When does Edgewise Therapeutics earnings report?

The next expected earnings date for Edgewise Therapeutics is 21 February 2025